Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
Lilly pulls out of CNS portion of $960M collab with Rigel
Eli Lilly has pulled out of the CNS portion of a $960 million biobucks deal centered on Rigel’s RIPK1 inhibitors.
James Waldron
Nov 5, 2025 7:00am
MapLight goes public via $250M IPO to fund Cobenfy competitor
Oct 27, 2025 6:45am
MapLight illuminates $262M IPO plans to fund Cobenfy competitor
Oct 7, 2025 6:30am
Julius attaches roots to Peachtree in CRO merger
May 14, 2025 2:52pm
Lilly saves gene therapy biotech with $18M upfront deal
Apr 3, 2025 6:00pm
Study reveals expanding gene that causes Huntington's disease
Jan 17, 2025 5:00pm
